
|Articles|August 1, 2003
Melanoma Survival Rate and Vitiligo
Author(s)Walter Alexander
Chicago - Among patients receiving a novel immune-based maintenance biotherapy regimen (mBT) for metastatic melanoma, those who developed vitiligo had longer median survival.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











